Nykode Therapeutics (Vaccibody) småprat (NYKD)

[Boms]

Ettersom dette bare er pre-kliniske data, tipper jeg at dette forsøk som viser bruk på både mRNA og DNA vaksiner. Hintet jeg baserer det på ligger i tittelen på foredraget som ikke kom med i den første posten.

[safin]

Något som fått med sig vad som blev presenterat idag?

[Boms]

Denne ligger nå ute på deres webside:

240501_NeoAg-summit_Europe_Fredriksen-1.pdf

Ser ut som om det er kun fokus på NEO vaksinen, og en blanding av kliniske resultater for DNA vaksinen og pre-klinisk for en mRNA vaksine. Noen dyp tolkning skal nok andre med bedre utdannelse innen faget enn meg gjøre.

[beholdning]

[safin]

Nykode Therapeutics følger fast-to-market-strategi for HPV16-målrettet kreftvaksine 2. mai 2024 | Catherine Shaffer NEW YORK – Nykode Therapeutics forfølger en rask-til-markedsstrategi for sin HPV16-målrettede vaksine mot avansert livmorhalskreft, men firmaet mener at deres vaksiner potensielt kan behandle pre-malign til sent stadium sykdom i flere tumortyper. https://www.precisionmedicineonline.com/precision-oncology/nykode-therapeutics-pursuing-fast-market-strategy-hpv16-targeted-cancer-vaccine.

[TekBot]

Nykode Therapeutics – invitation to Q1 2024 financial results presentation

Oslo, Norway, May 7, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will release its first quarter 2024 financial results before the opening of financial markets on Tuesday, May 14, 2024.

The Company will host a subsequent webcast presentation to review the financial and operating results. A question-and-answer session will follow.
…

Vis børsmeldingen

First Quarter 2024 Webcast:

Date: Tuesday, May 14, 2024
Time: 4 p.m. CET / 10 a.m. ET
Webcast: Nykode Therapeutics – Q1 2024 Financial Results Presentation - 1670178

The financial report, as well as a live and archived webcast of the presentation, can be accessed in the Financial Reports and Presentations section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[beholdning]

12.05.24 – Nykode Therapeutics – Aksjefrue.no

NYKD sett fra TA perspektiv

[beholdning]

Vaksine gir nytt håp i kampen mot aggressiv hjernekreft

Nykd nevnt i slutten av artikkelen.

[TekBot]

Nykode Therapeutics - Quarterly report Q1 2024

Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024.

The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations.
…

Vis børsmeldingen

The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: Nykode Therapeutics – Q1 2024 Financial Results Presentation - 1670178

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[TekBot]

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy.

VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The cancer vaccine is built on Nykode’s technology platform of targeting antigens to antigen presenting cells. Nykode has reported promising data from the phase 2 VB C-02 trial (NCT04405349) in heavily pre-treated cervical cancer patients receiving VB10.16 in combination with atezolizumab with a median overall survival not yet reached (estimated to 25 months at the time of analysis). These data support Nykode’s ongoing efforts with the phase 2 VB-C-04 trial (NCT06099418) in second-line recurrent/metastatic cervical cancer. Furthermore, the VB10.16 clinical development program is expanding into new indications, including head and neck cancer, for which Nykode has an existing clinical trial collaboration and supply agreement with MSD for the ongoing VB-C-03 trial (NCT06016920) evaluating VB10.16 in combination with KEYTRUDA in patients with HPV16-positive, PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma.
…

Vis børsmeldingen

Agnete Fredriksen, EVP, Chief Scientific Officer and Business Development, commented, “We are excited to expand our clinical development to include earlier stages of cervical cancer where there is a significant unmet medical need, and we see a huge potential for cancer vaccines. We are thrilled to continue building on our already established, highly valued collaboration with the experienced and talented team at MSD, a global leader in immuno-oncology.”

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
EVP, Chief Scientific Officer and Business Development, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde

[Boms]

Sponsing av KEYTRUDA til forsøk med VB10.16 til pasienter som får både Keytruda/pebrolizumab og kjemoterapi er helt klart et lyspunkt. At MSD synes dette er interessant er jo en liten validering av det Nykode holder med på i denne indikasjonen.

Ellers så er det jo to eventer i Q2 som vi får vente litt til på som kan gi håp om at det skjer noe i aksjen snart

[polygon]

VB-C-04 er altså i pasienter som ikke responderte på PD-1 hemmer. At de nå får en ny studie (VB-C-05) som forsøkes sammen med PD-1 hemmer i pasienter som er naive for dette kompletterer deres forsøk i denne kreftformen

Men det mangler en del info her synes jeg. Hvor stor er den? Er den randomiset? Når er den planlagt startet? Når er den planlagt å lese av? Man skulle jo tro at disse tingene allerede er bestemt i samråd med MSD?

[theroger]

[Boms]

Presentasjonen ligger nå ute og webcast starter om 1 minutt:

Nykode Therapeutics - Q1 2024 Financial Results – presentation - Nykode

[Pk2k]

Vatne fortsetter dumpingen, 1mill reduksjon

[Boms]

Kjipt å bli skvist ut av aksjen på disse bunnkursene. Håper det ikke er for mye gearing i aksjen nå.

[safin]

Han är väl konk

[Boms]

Håper det ikke er så ille, for jeg ønsker ingen den skjebnen selv om det alltid er en risk for de som spiller høyt.

[TraderJoe]

Det ser ut som om dette er tvangssalg som gjennomføres i regi av DNB. 1 mill aksjer overføres til DNB Markets som deretter prøver å bli kvitt dem - enten direkte til kunder eller over børs. Mønsteret var det samme ved forrige salg av 1 mill aksjer…

15.05.2024: Vatne Equity: -1.000.000 aksjer → DNB Markets Aksjehandel og analyse: +~554.000 aksjer
07.05.2024: Vatne Equity: -1.000.000 aksjer → DNB Markets Meglerkonto innland: + ~621.000

[Midlang86]

Tviler på mr Vatne er i skvis, lettere å selge dette antallet til DNB, for en % lavere enn sluttkurs for så at de meglerene selger de ut igjen.